Biolife solutions stock.
Dec 4, 2023 · BioLife Solutions Trading Up 2.5 %. NASDAQ BLFS traded up $0.33 on Monday, hitting $13.58. 44,504 shares of the stock were exchanged, compared to its average volume of 403,529. The company’s 50 ...
View the latest BioLife Solutions Inc. (BLFS) stock price, news, historical charts, analyst ratings and financial information from WSJ.Culture supplement to replace FBS or AB Serum. Biodefined composition reduces lot-to-lot variability. Supports a wide range of cell types including MSCs, T-Cells, NK Cells, Endothelial cells, and more. Promotes improved in vitro and In vivo cell quality in CAR-T applications. Typically used at concentrations ranging from 2% to 10%.Sep 1, 2021 · BOTHELL, Wash., Sept. 1, 2021 / PRNewswire / -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has closed its acquisition of Sexton Biotechnologies ... The BioLife Solutions stock price fell by -6.21% on the last day (Wednesday, 18th Oct 2023) from $12.39 to $11.62. During the last trading day the stock fluctuated 5.35% from a day low at $11.59 to a day high of $12.21. The price has fallen in 5 of the last 10 days and is down by -14.5% for this period. Volume fell on the last day along with ...7 dic 2020 ... Thomas Girschweiler sold 1600000 shares, an approximate value of $36 million, of the BioLife Solutions' stock to Casdin Capital LLC.
BLFS BioLife Solutions stock chart. #fintwits #money #wallstreet #stockmarket #stocks. 0 points. 1 comment. 1. 0 comments. share. save. 2. Posted by 2 years ago. I want to buy a trading bot, any recommendations here? 2. 3 comments. share. save. 1. Posted by 2 years ago. Adam Khoo FX trading. Hello! I got some courses a while back and have decided to …
BOTHELL, Wash., Jan. 10, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced preliminary revenue for the fourth quarter and full year 2021.BioLife Solutions is trading near 52-week lows as its growth story has floundered and profitability remains uncertain. Learn why I rate BLFS stock a hold.
BioLife Solutions, Inc. (BLFS) Stock Price, Quote, News & Analysis BLFS BioLife Solutions, Inc. Stock Price & Overview 5.43K followers $10.95 -0.44 ( -3.86%) 4:00 PM 11/10/23 NASDAQ...On December 15, 2022, BioLife Solutions, Inc. (NASDAQ:BLFS) stock closed at $18.77 per share. One-month return of BioLife Solutions, Inc. (NASDAQ:BLFS) was -11.46%, and its shares lost 48.63% of ...BioLife Solutions Biopreservation Media Products Outperform Traditional, Non-Optimized Formulations BOTHELL, WA-January 27, 2012- BioLife Solutions Inc.( OTC BB: BLFS), a leading developer, manufacturer, and marketer of proprietary hypothermic storage and cryopreservation freeze media for cells and tissues, today …While BioLife Solutions, Inc. ( NASDAQ:BLFS) might not be the most widely known stock at the moment, it saw significant share price movement during recent months on the NASDAQCM, rising to highs ...BioLife Solutions's headquarters are located at 3303 Monte Villa Pkwy Ste 310, Bothell, Washington, 98021, United States What is BioLife Solutions's phone number? BioLife Solutions's phone number is (425) 402-1400 What is BioLife Solutions's stock symbol?
BioLife Solutions, Inc. (NASDAQ:BLFS) Q3 2023 Earnings Call Transcript November 9, 2023 BioLife Solutions, Inc. beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.38. Operator: Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Third Quarter 2023 Shareholder and Analyst ...
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
BOTHELL, Wash., Dec. 19, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced plans to announce preliminary 2022 revenue and introduce 2023 revenue guidance before market open on ...Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...BioLife Solutions, Inc. (BLFS) Stock Price, News, Quote & History - Yahoo Finance Canada markets close in 5 hours 5 minutes S&P/TSX 20,174.44 +60.48(+0.30%) S&P …Complete BioLife Solutions Inc. stock information by Barron's. View real-time BLFS stock price and news, along with industry-best analysis. Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and BLFS is experiencing ...Open 18.44. Day High 18.95. Day Low 18.17. Prev Close 18.25. 52 Week High 26.96. 52 Week High Date 09/08/22. 52 Week Low 10.40. 52 Week Low Date 05/12/22. Market Cap 812.385M.Register here to receive email notifications with updates about our press releases, stock price, SEC filings and more. Presentations & Webcasts. Investor Presentation. ... BioLife Solutions Inc. 3303 Monte Villa Parkway, Suite 310, Bothell, WA 98021 USA. T +1.866.424.6543 or 425.402.1400 F +1.425.402.1433 E …
Maximize post-thaw cell recovery and viability following cryopreservation at low temperatures (-80°C to -196°C) with ready-to-use CryoStor® CS5. Serum-free, animal component-free, and cGMP-manufactured, this defined medium provides a safe, protective environment for cells and tissues during freezing and thawing processes and storage.BOTHELL, Wash., July 7, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the closing of its public offering of 5,951,250 shares of common stock at the public offering price of $14.50 …... Stock, $0.001 par value of BioLife Solutions, Inc. shall be filed on behalf of the undersigned. November 27, 2020. (Date). Casdin Capital, LLC. By: /s/ Eli ...Track Biolife Solutions Inc (BLFS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
--BioLife Solutions, Inc., ... BioLife will issue 6,646,870 shares of common stock for 100% of the outstanding shares of Stirling in an all-stock transaction, which is expected to close early in ...BioLife Solutions, Inc. Common Stock (BLFS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
Nov 30, 2023 · BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. The business earned $33.33 million during the quarter, compared to the consensus estimate of $33.28 million. BioLife Solutions has generated ($2.37) earnings per share over the last year (($2.37) diluted earnings per share). Earnings for BioLife Solutions are expected to grow in the coming year, from ($1.06) to ($0.26) per share.While BioLife Solutions, Inc. ( NASDAQ:BLFS) might not be the most widely known stock at the moment, it saw significant share price movement during recent months on the NASDAQCM, rising to highs ...BioLife Solutions is a leading supplier of class-defining cell and gene therapy bioproduction tools and services. Our tools portfolio includes our proprietary CryoStor® freeze media and ...See BioLife Solutions, Inc. (BLFS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.The current BioLife Solutions [ BLFS] share price is $13.57. The Score for BLFS is 44, which is 12% below its historic median score of 50, and infers higher risk than normal. BLFS is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on BioLife Solutions. The company’s shares closed last Thursday at $12.42, close to its 52-week low of $12.11.BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.The estimated net worth of Aby J. Mathew is at least $3.52 million as of November 13th, 2023. Dr. Mathew owns 275,726 shares of BioLife Solutions stock worth more than $3,521,021 as of November 18th. This net worth estimate does not reflect any other assets that Dr. Mathew may own.
BOTHELL, Wash., Dec. 19, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced plans to announce preliminary 2022 revenue and introduce 2023 revenue guidance before market open on ...
BioLife Solutions, Inc. Owego, New York. We have audited the accompanying Balance Sheets of BioLife Solutions, Inc. as of December 31, 2006 and 2005, and the related Statements of Operations, Stockholders’ Equity and Cash Flows for the years then ended. These financial statements are the responsibility of the Company’s management.
May 3, 2021 · BioLife issued 6,646,870 shares of common stock in exchange for 100% of the outstanding shares of Stirling. BioLife management has provided guidance for Stirling's 2021 post-closing revenue contribution to be $35 million to $37 million , with total 2021 revenue of $101 million to $110 million . First, BioLife Solutions, Inc. stock is trading at 1.95x book value of equity, which may or may not represent a value proposition. However, it should also be noted the breakdown of its book value ...Track Biolife Solutions Inc (BLFS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsBioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 29.17% and 4.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?BioLife Solutions, Inc. announced that it has entered into a Securities Purchase Agreement with returning investor, Casdin Partners Master Fund, L.P. managed by Casdin Capital, LLC that it has issued 927,165 shares of common stock of the Company, par value $0.001 per share at a purchase price of $11.19 per share for an aggregate gross proceeds ...While BioLife Solutions, Inc. ( NASDAQ:BLFS) might not be the most widely known stock at the moment, it saw significant share price movement during recent months on the NASDAQCM, rising to highs ...BioT™ ULT Transporter maintains samples at -50°C for 24 hours. BioT LN2 Transporter maintains cryogenic temperature at -150°C for approximately 2 hours. Ready to use in approximately 10 minutes. Lightweight, easy to …BioLife Solutions, Inc. reaffirmed 2023 revenue guidance for the fiscal 2023. For the period, the company expects revenue to range from $188 million to $202 million, reflecting year-over-year growth...Chief Quality Officer Of Biolife Solutions Trades $760K In Company Stock. (Benzinga) Sep-20-21 08:00AM. BioLife Solutions Appoints Joydeep Goswami, MBA, PhD to Board of Directors. (PR Newswire) BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings ...
Dec 4, 2023 · BioLife Solutions Trading Up 2.5 %. NASDAQ BLFS traded up $0.33 on Monday, hitting $13.58. 44,504 shares of the stock were exchanged, compared to its average volume of 403,529. The company’s 50 ... BioLife Solutions (NASDAQ:BLFS) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the superior stock?We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership, media sentiment and community ranking.Instagram:https://instagram. estsoftprivate equity stocksstocks for under 5b8 alpina BioLife Solutions Stock Performance. BLFS stock opened at $14.08 on Monday. The business has a 50 day moving average of $12.13 and a 200-day moving average of $16.47. BioLife Solutions, Inc. has a 12-month low of $8.92 and a 12-month high of $26.89. The firm has a market cap of $619.96 million, a PE ratio of -5.94 and a beta of 1.57. 1776 quarter worthdiscount futures broker First, BioLife Solutions, Inc. stock is trading at 1.95x book value of equity, which may or may not represent a value proposition. However, it should also be noted the breakdown of its book value ... 10 year treasury futures Oct 19, 2023 · Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 [email protected] Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Mar 22, 2021 · BioLife will issue 6,646,870 shares of common stock for 100% of the outstanding shares of Stirling in an all-stock transaction, which is expected to close early in the second quarter of 2021. With Stirling, BioLife believes that total GAAP revenue in 2021 will exceed $100 million and the transaction is expected to be accretive on an adjusted ...